Lifestyle interventions for physical health conditions in patients with schizophrenia

doi:10.3969/j.issn.1006-7795.2019.05.007

Abstract

Abstract: The physical health problems in schizophrenia are prominent, especially obesity and metabolic and cardiovascular diseases. Lifestyle interventions including physical activity and dietary adjustment are recommended as non-drug interventions for obesity and other related medical conditions. The paper summarized recent studies on lifestyle intervention in patients with schizophrenia. It has been proved that lifestyle interventions have a significant effect on weight loss but a less obvious effects on blood pressure, glucose and waist-hip ratio control. It may shed light on correlation between physical health problems of patients with schizophrenia and the community management and treatment services of severe mental disorders in China. The influence of lifestyle interventions in the community rehabilitation on the physical health problems of patients with schizophrenia should be concerned.

Key words: schizophrenia, metabolic syndrome, behavioral intervention

CLC Number:

R749.3

Zhuang Wenxu, Zhang Weibo, Zhu Youwei, Zhu Yi, Cai Jun. Lifestyle interventions for physical health conditions in patients with schizophrenia[J]. Journal of Capital Medical University, 2019, 40(5): 698-702.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2019.05.007

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2019/V40/I5/698

References

[1] Hjorthøj C, Stürup A E, McGrath J J, et al. Years of potential life lost and life expectancy in schizophrenia:a systematic review and meta-analysis[J]. Lancet Psychiatry, 2017, 4(4):295-301.
[2] Dickerson F, Origoni A, Schroeder J, et al. Mortality in schizophrenia and bipolar disorder:clinical and serological predictors[J]. Schizophr Res, 2016, 170(1):177-183.
[3] Olfson M, Gerhard T, Huang C, et al. Premature mortality among adults with schizophrenia in the united states[J]. JAMA psychiatry, 2015, 72(12):1172-1181.
[4] Cooper S J, Reynolds G P, Barnes T, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment[J]. J Psychopharmacol,2016, 30(8):717-748.
[5] Vancampfort D, Stubbs B, Mitchell A J, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder:a systematic review and meta-analysis[J]. World Psychiatry,2015,14(3):339-347.
[6] Andrade C. Cardiometabolic Risks in schizophrenia and directions for intervention, 1:magnitude and moderators of the problem[J]. J Clin Psychiatry,2016,77(7):e844-847.
[7] Webb V L, Wadden T A. Intensive lifestyle intervention for obesity:principles, practices, and results[J]. Gastroenterology, 2017, 152(7):1752-1764.
[8] Gorter K J, van de Laar F A, Janssen P G, et al. Diabetes:glycaemic control in type 2(drug treatments)[J]. BMJ Clin Evid, 2012,2012. pill:0609.
[9] Gay H C, Rao S G, Vaccarino V, et al. Effects of different dietary interventions on blood pressure:systematic review and meta-analysis of randomized controlled trials[J]. Hypertension, 2016, 67(4):733-739.
[10] Annamalai A, Tek C. An overview of diabetes management in schizophrenia patients:office based strategies for primary care practitioners and endocrinologists[J]. Int J Endocrinol, 2015,2015:969182.
[11] Kuipers E, Yesufu-Udechuku A, Taylor C, et al. Management of psychosis and schizophrenia in adults:summary of updated NICE guidance[J]. BMJ, 2014, 348:g1173.
[12] Allison D B, Newcomer J W, Dunn A L, et al. Obesity among those with mental disorders:a National Institute of Mental Health meeting report[J]. Am J Prev Med, 2009, 36(4):341-350.
[13] Pallava A, Chadda R K, Sood M, et al. Metabolic syndrome in schizophrenia:A comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India[J]. Nord J Psychiatry, 2012, 66(3):215-221.
[14] Chaggar P S, Shaw S M, Williams S G. Effect of antipsychotic medications on glucose and lipid levels[J]. J Clin Pharmacol, 2011, 51(5):631-638.
[15] Kilbourne A M, Morden N E, Austin K, et al. Excess heart-disease-related mortality in a national study of patients with mental disorders:identifying modifiable risk factors[J]. Gen Hosp Psychiatry, 2009, 31(6):555-563.
[16] Kilbourne A M, McCarthy J F, Post E P, et al. Access to and satisfaction with care comparing patients with and without serious mental illness[J]. Int J Psychiatry Med, 2006, 36(4):383-399.
[17] Peet M. Nutrition and schizophrenia:an epidemiological and clinical perspective[J]. Nutr Health, 2003, 17(3):211-219.
[18] Dickey B, Normand S L T, Weiss R D, et al. Medical morbidity, mental illness, and substance use disorders[J]. Psychiatr Serv, 2002, 53(7):861-867.
[19] Dipasquale S, Pariante C M, Dazzan P, et al. The dietary pattern of patients with schizophrenia:a systematic review[J]. J Psychiatr Res, 2013, 47(2):197-207.
[20] Daumit G L, Goldberg R W, Anthony C, et al. Physical activity patterns in adults with severe mental illness[J]. J Nerv Ment Dis, 2005, 193(10):641-646.
[21] Vancampfort D, Firth J, Correll C U, et al. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia:a meta-review of meta-analyses of randomized controlled trials[J]. World Psychiatry, 2019, 18(1):53-66.
[22] Gabriele J M, Dubbert P M, Reeves R R. Efficacy of behavioural interventions in managing atypical antipsychotic weight gain[J]. Obes Rev, 2009, 10(4):442-455.
[23] Daumit G L, Dickerson F B, Wang N Y, et al. A behavioral weight-loss intervention in persons with serious mental illness[J]. N Engl J Med, 2013, 368(17):1594-1602.
[24] Steinberg D, Bennett G G, Svetkey L. The DASH diet, 20 years later[J]. JAMA, 2017, 317(15):1529-1530.
[25] Green C A, Yarborough B J, Leo M C, et al. The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications:a randomized trial[J]. Am J Psychiatry, 2015, 172(1):71-81.
[26] Green C A, Yarborough B J, Leo M C, et al. Weight maintenance following the STRIDE lifestyle intervention for individuals taking antipsychotic medications[J]. Obesity, 2015, 23(10):1995-2001.
[27] Vancampfort D, Stubbs B, Mitchell A J, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder:a systematic review and meta-analysis[J]. World Psychiatry, 2015, 14(3):339-347.
[28] Enez Darcin A, Yalcin Cavus S, Dilbaz N, et al. Metabolic syndrome in drug-naïve and drug-free patients with schizophrenia and in their siblings[J]. Schizophr Res, 2015, 166(1-3):201-206.
[29] Centorrino F, Wurtman J J, Duca K A, et al. Weight loss in overweight patients maintained on atypical antipsychotic agents[J]. Int J Obes, 2006, 30(6):1011-1016.
[30] Menza M, Vreeland B, Minsky S, et al. Managing atypical antipsychotic-associated weight gain:12-month data on a multimodal weight control program[J]. J Clin Psychiatry, 2004,65(4):471-477
[31] McKibbin C L, Patterson T L, Norman G, et al. A lifestyle intervention for older schizophrenia patients with diabetes mellitus:a randomized controlled trial[J]. Schizoph Res, 2006, 86(1-3):36-44.
[32] Bartels S J, Pratt S I, Aschbrenner K A, et al. Clinically significant improved fitness and weight loss among overweight persons with serious mental illness[J]. Psychiatr Servi, 2013, 64(8):729-736.
[33] Zhou F C, Zheng W, Lu L, et al. Prospective memory in schizophrenia:a meta-analysis of comparative studies[J]. Schizophr Res, 2019,pii:S0920-9964(19)30351-2.
[34] Goughari A S, Mazhari S, Pourrahimi A M, et al. Associations between components of metabolic syndrome and cognition in patients with schizophrenia[J]. J Psychiatri Pract, 2015, 21(3):190-197.
[35] 孙岩,赵敏. 精神分裂症心理社会康复:国内研究十年回顾[J]. 精神医学杂志, 2018, 31(3):231-236.
[36] 国家卫生健康委员会. 严重精神障碍管理治疗工作规范(2018年版)[EB/OL].(2018-05-28)[2018-06-08].http://www.nhc.gov.cn/jkj/s7932/201806/90d5fe3b7f48453db9b9beb85dfdc8a8.shtml